Patent intelligence · US
US 8283461
Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
Patent details — US 8283461
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 9, 2012
- Expiration
- Oct 4, 2032
- Applicant
- Benitec, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K38/00, A61P, A61P1/16
Quick answer
US 8283461 (Multiple promoter expression cassettes for simultaneous delivery of RNAi agents) is held by Benitec, Inc.. Status: granted. Granted Oct 9, 2012. Expires Oct 4, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Benitec, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/00, A61P, A61P1/16, A61P31/12, A61P31/14
More from Benitec, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11932852
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 11535851
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
granted -
US 11234994
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 11142765
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 10898505
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
granted -
US 10000753
Age-related macular degeneration treatment
granted -
US 9518260
Pain treatment
granted -
US 9410154
HBV treatment
granted
Frequently asked questions
What is US patent 8283461?
US 8283461 (Multiple promoter expression cassettes for simultaneous delivery of RNAi agents) is held by Benitec, Inc.. Status: granted. Granted Oct 9, 2012. Expires Oct 4, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8283461?
Benitec, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 8283461 expire?
Our index shows an expiration date of Oct 4, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.